Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Growth 2026-2032
The global Monoclonal Antibodies for Non-small Cell Lung Cancer market size is predicted to grow from US$ 13990 million in 2025 to US$ 29780 million in 2032; it is expected to grow at a CAGR of 11.6% from 2026 to 2032.
Non-Monoclonal Antibodies for Non-small Cell Lung Cancer are a class of biological agents targeting specific targets of non-small cell lung cancer (NSCLC), aiming to enhance the body's immune response by targeting specific antigens or immune checkpoints on the surface of cancer cells, thereby inhibiting tumor growth and metastasis. These monoclonal antibodies can be used to treat advanced or recurrent NSCLC, often in combination with chemotherapy or other immunotherapies, to increase treatment efficacy and improve patient survival.
United States market for Monoclonal Antibodies for Non-small Cell Lung Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Monoclonal Antibodies for Non-small Cell Lung Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Monoclonal Antibodies for Non-small Cell Lung Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Monoclonal Antibodies for Non-small Cell Lung Cancer players cover Roche Holding AG, Bristol Myers Squibb Co., Elea Spa, Eli Lilly & Co., Merck & Co., Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Monoclonal Antibodies for Non-small Cell Lung Cancer Industry Forecast? looks at past sales and reviews total world Monoclonal Antibodies for Non-small Cell Lung Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected Monoclonal Antibodies for Non-small Cell Lung Cancer sales for 2026 through 2032. With Monoclonal Antibodies for Non-small Cell Lung Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Monoclonal Antibodies for Non-small Cell Lung Cancer industry.
This Insight Report provides a comprehensive analysis of the global Monoclonal Antibodies for Non-small Cell Lung Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Monoclonal Antibodies for Non-small Cell Lung Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Monoclonal Antibodies for Non-small Cell Lung Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Monoclonal Antibodies for Non-small Cell Lung Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Monoclonal Antibodies for Non-small Cell Lung Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of Monoclonal Antibodies for Non-small Cell Lung Cancer market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Monoclonal Antibodies for Non-small Cell Lung Cancer market?
What factors are driving Monoclonal Antibodies for Non-small Cell Lung Cancer market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Monoclonal Antibodies for Non-small Cell Lung Cancer market opportunities vary by end market size?
How does Monoclonal Antibodies for Non-small Cell Lung Cancer break out by Type, by Application?
Non-Monoclonal Antibodies for Non-small Cell Lung Cancer are a class of biological agents targeting specific targets of non-small cell lung cancer (NSCLC), aiming to enhance the body's immune response by targeting specific antigens or immune checkpoints on the surface of cancer cells, thereby inhibiting tumor growth and metastasis. These monoclonal antibodies can be used to treat advanced or recurrent NSCLC, often in combination with chemotherapy or other immunotherapies, to increase treatment efficacy and improve patient survival.
United States market for Monoclonal Antibodies for Non-small Cell Lung Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Monoclonal Antibodies for Non-small Cell Lung Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Monoclonal Antibodies for Non-small Cell Lung Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Monoclonal Antibodies for Non-small Cell Lung Cancer players cover Roche Holding AG, Bristol Myers Squibb Co., Elea Spa, Eli Lilly & Co., Merck & Co., Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Monoclonal Antibodies for Non-small Cell Lung Cancer Industry Forecast? looks at past sales and reviews total world Monoclonal Antibodies for Non-small Cell Lung Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected Monoclonal Antibodies for Non-small Cell Lung Cancer sales for 2026 through 2032. With Monoclonal Antibodies for Non-small Cell Lung Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Monoclonal Antibodies for Non-small Cell Lung Cancer industry.
This Insight Report provides a comprehensive analysis of the global Monoclonal Antibodies for Non-small Cell Lung Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Monoclonal Antibodies for Non-small Cell Lung Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Monoclonal Antibodies for Non-small Cell Lung Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Monoclonal Antibodies for Non-small Cell Lung Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Monoclonal Antibodies for Non-small Cell Lung Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of Monoclonal Antibodies for Non-small Cell Lung Cancer market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- 5 mg/mL
- 10 mg/mL
- 25 mg/mL
- 50 mg/mL
- Hospitals
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Roche Holding AG
- Bristol Myers Squibb Co.
- Elea Spa
- Eli Lilly & Co.
- Merck & Co., Inc.
- AstraZeneca PLC
- Regeneron Pharmaceuticals, Inc.
- Henlius Biopharma Co., Ltd
- Jiangsu Hengrui Medicine Co., Ltd
- Innovent Biologics Co., Ltd
- Junshi Biosciences Co., Ltd
- BeiGene, Ltd
- Akeso, Inc
What is the 10-year outlook for the global Monoclonal Antibodies for Non-small Cell Lung Cancer market?
What factors are driving Monoclonal Antibodies for Non-small Cell Lung Cancer market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Monoclonal Antibodies for Non-small Cell Lung Cancer market opportunities vary by end market size?
How does Monoclonal Antibodies for Non-small Cell Lung Cancer break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Monoclonal Antibodies for Non-small Cell Lung Cancer by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Monoclonal Antibodies for Non-small Cell Lung Cancer by Country/Region, 2021, 2025 & 2032
2.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Segment by Type
2.2.1 5 mg/mL
2.2.2 10 mg/mL
2.2.3 25 mg/mL
2.2.4 50 mg/mL
2.2.5 Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type
2.2.5.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2021-2026)
2.2.5.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Price by Type (2021-2026)
2.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Segment by Application
2.3.1 Hospitals
2.3.2 Clinic
2.3.3 Others
2.3.4 Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application
2.3.4.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Market Share by Application (2021-2026)
2.3.4.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Breakdown Data by Company
3.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales by Company (2021-2026)
3.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Company (2021-2026)
3.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue by Company (2021-2026)
3.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Company (2021-2026)
3.2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Company (2021-2026)
3.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Price by Company
3.4 Key Manufacturers Monoclonal Antibodies for Non-small Cell Lung Cancer Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Monoclonal Antibodies for Non-small Cell Lung Cancer Product Location Distribution
3.4.2 Players Monoclonal Antibodies for Non-small Cell Lung Cancer Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR MONOCLONAL ANTIBODIES FOR NON-SMALL CELL LUNG CANCER BY GEOGRAPHIC REGION
4.1 World Historic Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Geographic Region (2021-2026)
4.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country/Region (2021-2026)
4.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales by Country/Region (2021-2026)
4.2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue by Country/Region (2021-2026)
4.3 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Growth
4.4 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Growth
4.5 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Growth
4.6 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Growth
5 AMERICAS
5.1 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country
5.1.1 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2021-2026)
5.1.2 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2021-2026)
5.2 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026)
5.3 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region
6.1.1 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2021-2026)
6.1.2 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2021-2026)
6.2 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026)
6.3 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer by Country
7.1.1 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2021-2026)
7.1.2 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2021-2026)
7.2 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026)
7.3 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer by Country
8.1.1 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2021-2026)
8.1.2 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2021-2026)
8.2 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026)
8.3 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer
10.3 Manufacturing Process Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer
10.4 Industry Chain Structure of Monoclonal Antibodies for Non-small Cell Lung Cancer
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Distributors
11.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Customer
12 WORLD FORECAST REVIEW FOR MONOCLONAL ANTIBODIES FOR NON-SMALL CELL LUNG CANCER BY GEOGRAPHIC REGION
12.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size Forecast by Region
12.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Forecast by Region (2027-2032)
12.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Forecast by Type (2027-2032)
12.7 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Roche Holding AG
13.1.1 Roche Holding AG Company Information
13.1.2 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.1.3 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Roche Holding AG Main Business Overview
13.1.5 Roche Holding AG Latest Developments
13.2 Bristol Myers Squibb Co.
13.2.1 Bristol Myers Squibb Co. Company Information
13.2.2 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.2.3 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bristol Myers Squibb Co. Main Business Overview
13.2.5 Bristol Myers Squibb Co. Latest Developments
13.3 Elea Spa
13.3.1 Elea Spa Company Information
13.3.2 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.3.3 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Elea Spa Main Business Overview
13.3.5 Elea Spa Latest Developments
13.4 Eli Lilly & Co.
13.4.1 Eli Lilly & Co. Company Information
13.4.2 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.4.3 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Eli Lilly & Co. Main Business Overview
13.4.5 Eli Lilly & Co. Latest Developments
13.5 Merck & Co., Inc.
13.5.1 Merck & Co., Inc. Company Information
13.5.2 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.5.3 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Merck & Co., Inc. Main Business Overview
13.5.5 Merck & Co., Inc. Latest Developments
13.6 AstraZeneca PLC
13.6.1 AstraZeneca PLC Company Information
13.6.2 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.6.3 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 AstraZeneca PLC Main Business Overview
13.6.5 AstraZeneca PLC Latest Developments
13.7 Regeneron Pharmaceuticals, Inc.
13.7.1 Regeneron Pharmaceuticals, Inc. Company Information
13.7.2 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.7.3 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Regeneron Pharmaceuticals, Inc. Main Business Overview
13.7.5 Regeneron Pharmaceuticals, Inc. Latest Developments
13.8 Henlius Biopharma Co., Ltd
13.8.1 Henlius Biopharma Co., Ltd Company Information
13.8.2 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.8.3 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Henlius Biopharma Co., Ltd Main Business Overview
13.8.5 Henlius Biopharma Co., Ltd Latest Developments
13.9 Jiangsu Hengrui Medicine Co., Ltd
13.9.1 Jiangsu Hengrui Medicine Co., Ltd Company Information
13.9.2 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.9.3 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Jiangsu Hengrui Medicine Co., Ltd Main Business Overview
13.9.5 Jiangsu Hengrui Medicine Co., Ltd Latest Developments
13.10 Innovent Biologics Co., Ltd
13.10.1 Innovent Biologics Co., Ltd Company Information
13.10.2 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.10.3 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Innovent Biologics Co., Ltd Main Business Overview
13.10.5 Innovent Biologics Co., Ltd Latest Developments
13.11 Junshi Biosciences Co., Ltd
13.11.1 Junshi Biosciences Co., Ltd Company Information
13.11.2 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.11.3 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Junshi Biosciences Co., Ltd Main Business Overview
13.11.5 Junshi Biosciences Co., Ltd Latest Developments
13.12 BeiGene, Ltd
13.12.1 BeiGene, Ltd Company Information
13.12.2 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.12.3 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 BeiGene, Ltd Main Business Overview
13.12.5 BeiGene, Ltd Latest Developments
13.13 Akeso, Inc
13.13.1 Akeso, Inc Company Information
13.13.2 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.13.3 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Akeso, Inc Main Business Overview
13.13.5 Akeso, Inc Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Monoclonal Antibodies for Non-small Cell Lung Cancer by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Monoclonal Antibodies for Non-small Cell Lung Cancer by Country/Region, 2021, 2025 & 2032
2.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Segment by Type
2.2.1 5 mg/mL
2.2.2 10 mg/mL
2.2.3 25 mg/mL
2.2.4 50 mg/mL
2.2.5 Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type
2.2.5.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2021-2026)
2.2.5.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Price by Type (2021-2026)
2.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Segment by Application
2.3.1 Hospitals
2.3.2 Clinic
2.3.3 Others
2.3.4 Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application
2.3.4.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Market Share by Application (2021-2026)
2.3.4.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Breakdown Data by Company
3.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales by Company (2021-2026)
3.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Company (2021-2026)
3.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue by Company (2021-2026)
3.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Company (2021-2026)
3.2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Company (2021-2026)
3.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Price by Company
3.4 Key Manufacturers Monoclonal Antibodies for Non-small Cell Lung Cancer Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Monoclonal Antibodies for Non-small Cell Lung Cancer Product Location Distribution
3.4.2 Players Monoclonal Antibodies for Non-small Cell Lung Cancer Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR MONOCLONAL ANTIBODIES FOR NON-SMALL CELL LUNG CANCER BY GEOGRAPHIC REGION
4.1 World Historic Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Geographic Region (2021-2026)
4.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size by Country/Region (2021-2026)
4.2.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales by Country/Region (2021-2026)
4.2.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue by Country/Region (2021-2026)
4.3 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Growth
4.4 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Growth
4.5 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Growth
4.6 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Growth
5 AMERICAS
5.1 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country
5.1.1 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2021-2026)
5.1.2 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2021-2026)
5.2 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026)
5.3 Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region
6.1.1 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2021-2026)
6.1.2 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2021-2026)
6.2 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026)
6.3 APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer by Country
7.1.1 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2021-2026)
7.1.2 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2021-2026)
7.2 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026)
7.3 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer by Country
8.1.1 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2021-2026)
8.1.2 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2021-2026)
8.2 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026)
8.3 Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer
10.3 Manufacturing Process Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer
10.4 Industry Chain Structure of Monoclonal Antibodies for Non-small Cell Lung Cancer
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Monoclonal Antibodies for Non-small Cell Lung Cancer Distributors
11.3 Monoclonal Antibodies for Non-small Cell Lung Cancer Customer
12 WORLD FORECAST REVIEW FOR MONOCLONAL ANTIBODIES FOR NON-SMALL CELL LUNG CANCER BY GEOGRAPHIC REGION
12.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size Forecast by Region
12.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Forecast by Region (2027-2032)
12.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Forecast by Type (2027-2032)
12.7 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Roche Holding AG
13.1.1 Roche Holding AG Company Information
13.1.2 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.1.3 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Roche Holding AG Main Business Overview
13.1.5 Roche Holding AG Latest Developments
13.2 Bristol Myers Squibb Co.
13.2.1 Bristol Myers Squibb Co. Company Information
13.2.2 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.2.3 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bristol Myers Squibb Co. Main Business Overview
13.2.5 Bristol Myers Squibb Co. Latest Developments
13.3 Elea Spa
13.3.1 Elea Spa Company Information
13.3.2 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.3.3 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Elea Spa Main Business Overview
13.3.5 Elea Spa Latest Developments
13.4 Eli Lilly & Co.
13.4.1 Eli Lilly & Co. Company Information
13.4.2 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.4.3 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Eli Lilly & Co. Main Business Overview
13.4.5 Eli Lilly & Co. Latest Developments
13.5 Merck & Co., Inc.
13.5.1 Merck & Co., Inc. Company Information
13.5.2 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.5.3 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Merck & Co., Inc. Main Business Overview
13.5.5 Merck & Co., Inc. Latest Developments
13.6 AstraZeneca PLC
13.6.1 AstraZeneca PLC Company Information
13.6.2 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.6.3 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 AstraZeneca PLC Main Business Overview
13.6.5 AstraZeneca PLC Latest Developments
13.7 Regeneron Pharmaceuticals, Inc.
13.7.1 Regeneron Pharmaceuticals, Inc. Company Information
13.7.2 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.7.3 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Regeneron Pharmaceuticals, Inc. Main Business Overview
13.7.5 Regeneron Pharmaceuticals, Inc. Latest Developments
13.8 Henlius Biopharma Co., Ltd
13.8.1 Henlius Biopharma Co., Ltd Company Information
13.8.2 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.8.3 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Henlius Biopharma Co., Ltd Main Business Overview
13.8.5 Henlius Biopharma Co., Ltd Latest Developments
13.9 Jiangsu Hengrui Medicine Co., Ltd
13.9.1 Jiangsu Hengrui Medicine Co., Ltd Company Information
13.9.2 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.9.3 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Jiangsu Hengrui Medicine Co., Ltd Main Business Overview
13.9.5 Jiangsu Hengrui Medicine Co., Ltd Latest Developments
13.10 Innovent Biologics Co., Ltd
13.10.1 Innovent Biologics Co., Ltd Company Information
13.10.2 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.10.3 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Innovent Biologics Co., Ltd Main Business Overview
13.10.5 Innovent Biologics Co., Ltd Latest Developments
13.11 Junshi Biosciences Co., Ltd
13.11.1 Junshi Biosciences Co., Ltd Company Information
13.11.2 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.11.3 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Junshi Biosciences Co., Ltd Main Business Overview
13.11.5 Junshi Biosciences Co., Ltd Latest Developments
13.12 BeiGene, Ltd
13.12.1 BeiGene, Ltd Company Information
13.12.2 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.12.3 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 BeiGene, Ltd Main Business Overview
13.12.5 BeiGene, Ltd Latest Developments
13.13 Akeso, Inc
13.13.1 Akeso, Inc Company Information
13.13.2 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
13.13.3 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Akeso, Inc Main Business Overview
13.13.5 Akeso, Inc Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 5 mg/mL
Table 4. Major Players of 10 mg/mL
Table 5. Major Players of 25 mg/mL
Table 6. Major Players of 50 mg/mL
Table 7. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026) & (K Units)
Table 8. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2021-2026)
Table 9. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Type (2021-2026) & ($ million)
Table 10. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type (2021-2026)
Table 11. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale by Application (2021-2026) & (K Units)
Table 13. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Market Share by Application (2021-2026)
Table 14. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Application (2021-2026) & ($ million)
Table 15. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application (2021-2026)
Table 16. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Company (2021-2026) & (K Units)
Table 18. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Company (2021-2026)
Table 19. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Company (2021-2026)
Table 21. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Monoclonal Antibodies for Non-small Cell Lung Cancer Producing Area Distribution and Sales Area
Table 23. Players Monoclonal Antibodies for Non-small Cell Lung Cancer Products Offered
Table 24. Monoclonal Antibodies for Non-small Cell Lung Cancer Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share Geographic Region (2021-2026)
Table 29. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country/Region (2021-2026)
Table 33. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2021-2026) & (K Units)
Table 36. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2021-2026)
Table 37. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026) & (K Units)
Table 39. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026) & (K Units)
Table 40. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2021-2026) & (K Units)
Table 41. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region (2021-2026)
Table 42. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026) & (K Units)
Table 44. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026) & (K Units)
Table 45. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2021-2026) & (K Units)
Table 46. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026) & (K Units)
Table 48. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Monoclonal Antibodies for Non-small Cell Lung Cancer
Table 54. Key Market Challenges & Risks of Monoclonal Antibodies for Non-small Cell Lung Cancer
Table 55. Key Industry Trends of Monoclonal Antibodies for Non-small Cell Lung Cancer
Table 56. Monoclonal Antibodies for Non-small Cell Lung Cancer Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Monoclonal Antibodies for Non-small Cell Lung Cancer Distributors List
Table 59. Monoclonal Antibodies for Non-small Cell Lung Cancer Customer List
Table 60. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Roche Holding AG Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 75. Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 76. Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Roche Holding AG Main Business
Table 78. Roche Holding AG Latest Developments
Table 79. Bristol Myers Squibb Co. Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 80. Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 81. Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Bristol Myers Squibb Co. Main Business
Table 83. Bristol Myers Squibb Co. Latest Developments
Table 84. Elea Spa Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 85. Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 86. Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Elea Spa Main Business
Table 88. Elea Spa Latest Developments
Table 89. Eli Lilly & Co. Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 90. Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 91. Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Eli Lilly & Co. Main Business
Table 93. Eli Lilly & Co. Latest Developments
Table 94. Merck & Co., Inc. Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 95. Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 96. Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Merck & Co., Inc. Main Business
Table 98. Merck & Co., Inc. Latest Developments
Table 99. AstraZeneca PLC Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 100. AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 101. AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. AstraZeneca PLC Main Business
Table 103. AstraZeneca PLC Latest Developments
Table 104. Regeneron Pharmaceuticals, Inc. Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 105. Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 106. Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Regeneron Pharmaceuticals, Inc. Main Business
Table 108. Regeneron Pharmaceuticals, Inc. Latest Developments
Table 109. Henlius Biopharma Co., Ltd Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 110. Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 111. Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Henlius Biopharma Co., Ltd Main Business
Table 113. Henlius Biopharma Co., Ltd Latest Developments
Table 114. Jiangsu Hengrui Medicine Co., Ltd Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 115. Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 116. Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Jiangsu Hengrui Medicine Co., Ltd Main Business
Table 118. Jiangsu Hengrui Medicine Co., Ltd Latest Developments
Table 119. Innovent Biologics Co., Ltd Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 120. Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 121. Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Innovent Biologics Co., Ltd Main Business
Table 123. Innovent Biologics Co., Ltd Latest Developments
Table 124. Junshi Biosciences Co., Ltd Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 125. Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 126. Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Junshi Biosciences Co., Ltd Main Business
Table 128. Junshi Biosciences Co., Ltd Latest Developments
Table 129. BeiGene, Ltd Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 130. BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 131. BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. BeiGene, Ltd Main Business
Table 133. BeiGene, Ltd Latest Developments
Table 134. Akeso, Inc Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 135. Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 136. Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Akeso, Inc Main Business
Table 138. Akeso, Inc Latest Developments
Table 1. Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 5 mg/mL
Table 4. Major Players of 10 mg/mL
Table 5. Major Players of 25 mg/mL
Table 6. Major Players of 50 mg/mL
Table 7. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026) & (K Units)
Table 8. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2021-2026)
Table 9. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Type (2021-2026) & ($ million)
Table 10. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type (2021-2026)
Table 11. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale by Application (2021-2026) & (K Units)
Table 13. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Market Share by Application (2021-2026)
Table 14. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Application (2021-2026) & ($ million)
Table 15. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application (2021-2026)
Table 16. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Company (2021-2026) & (K Units)
Table 18. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Company (2021-2026)
Table 19. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Company (2021-2026)
Table 21. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Monoclonal Antibodies for Non-small Cell Lung Cancer Producing Area Distribution and Sales Area
Table 23. Players Monoclonal Antibodies for Non-small Cell Lung Cancer Products Offered
Table 24. Monoclonal Antibodies for Non-small Cell Lung Cancer Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share Geographic Region (2021-2026)
Table 29. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country/Region (2021-2026)
Table 33. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2021-2026) & (K Units)
Table 36. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2021-2026)
Table 37. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026) & (K Units)
Table 39. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026) & (K Units)
Table 40. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Region (2021-2026) & (K Units)
Table 41. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region (2021-2026)
Table 42. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026) & (K Units)
Table 44. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026) & (K Units)
Table 45. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2021-2026) & (K Units)
Table 46. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026) & (K Units)
Table 48. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Monoclonal Antibodies for Non-small Cell Lung Cancer
Table 54. Key Market Challenges & Risks of Monoclonal Antibodies for Non-small Cell Lung Cancer
Table 55. Key Industry Trends of Monoclonal Antibodies for Non-small Cell Lung Cancer
Table 56. Monoclonal Antibodies for Non-small Cell Lung Cancer Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Monoclonal Antibodies for Non-small Cell Lung Cancer Distributors List
Table 59. Monoclonal Antibodies for Non-small Cell Lung Cancer Customer List
Table 60. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Roche Holding AG Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 75. Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 76. Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Roche Holding AG Main Business
Table 78. Roche Holding AG Latest Developments
Table 79. Bristol Myers Squibb Co. Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 80. Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 81. Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Bristol Myers Squibb Co. Main Business
Table 83. Bristol Myers Squibb Co. Latest Developments
Table 84. Elea Spa Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 85. Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 86. Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Elea Spa Main Business
Table 88. Elea Spa Latest Developments
Table 89. Eli Lilly & Co. Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 90. Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 91. Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Eli Lilly & Co. Main Business
Table 93. Eli Lilly & Co. Latest Developments
Table 94. Merck & Co., Inc. Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 95. Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 96. Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Merck & Co., Inc. Main Business
Table 98. Merck & Co., Inc. Latest Developments
Table 99. AstraZeneca PLC Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 100. AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 101. AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. AstraZeneca PLC Main Business
Table 103. AstraZeneca PLC Latest Developments
Table 104. Regeneron Pharmaceuticals, Inc. Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 105. Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 106. Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Regeneron Pharmaceuticals, Inc. Main Business
Table 108. Regeneron Pharmaceuticals, Inc. Latest Developments
Table 109. Henlius Biopharma Co., Ltd Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 110. Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 111. Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Henlius Biopharma Co., Ltd Main Business
Table 113. Henlius Biopharma Co., Ltd Latest Developments
Table 114. Jiangsu Hengrui Medicine Co., Ltd Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 115. Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 116. Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Jiangsu Hengrui Medicine Co., Ltd Main Business
Table 118. Jiangsu Hengrui Medicine Co., Ltd Latest Developments
Table 119. Innovent Biologics Co., Ltd Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 120. Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 121. Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Innovent Biologics Co., Ltd Main Business
Table 123. Innovent Biologics Co., Ltd Latest Developments
Table 124. Junshi Biosciences Co., Ltd Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 125. Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 126. Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Junshi Biosciences Co., Ltd Main Business
Table 128. Junshi Biosciences Co., Ltd Latest Developments
Table 129. BeiGene, Ltd Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 130. BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 131. BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. BeiGene, Ltd Main Business
Table 133. BeiGene, Ltd Latest Developments
Table 134. Akeso, Inc Basic Information, Monoclonal Antibodies for Non-small Cell Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 135. Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product Portfolios and Specifications
Table 136. Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Akeso, Inc Main Business
Table 138. Akeso, Inc Latest Developments
LIST OF FIGURES
Figure 1. Picture of Monoclonal Antibodies for Non-small Cell Lung Cancer
Figure 2. Monoclonal Antibodies for Non-small Cell Lung Cancer Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country/Region (2025)
Figure 10. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 5 mg/mL
Figure 12. Product Picture of 10 mg/mL
Figure 13. Product Picture of 25 mg/mL
Figure 14. Product Picture of 50 mg/mL
Figure 15. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type in 2026
Figure 16. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type (2021-2026)
Figure 17. Monoclonal Antibodies for Non-small Cell Lung Cancer Consumed in Hospitals
Figure 18. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Hospitals (2021-2026) & (K Units)
Figure 19. Monoclonal Antibodies for Non-small Cell Lung Cancer Consumed in Clinic
Figure 20. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Clinic (2021-2026) & (K Units)
Figure 21. Monoclonal Antibodies for Non-small Cell Lung Cancer Consumed in Others
Figure 22. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Others (2021-2026) & (K Units)
Figure 23. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Market Share by Application (2025)
Figure 24. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application in 2026
Figure 25. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Company in 2026 (K Units)
Figure 26. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Company in 2026
Figure 27. Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Company in 2026 ($ millions)
Figure 28. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Company in 2026
Figure 29. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales 2021-2026 (K Units)
Figure 32. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue 2021-2026 ($ millions)
Figure 33. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales 2021-2026 (K Units)
Figure 34. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue 2021-2026 ($ millions)
Figure 35. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales 2021-2026 (K Units)
Figure 36. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue 2021-2026 ($ millions)
Figure 39. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country in 2026
Figure 40. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2021-2026)
Figure 41. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2021-2026)
Figure 42. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2021-2026)
Figure 43. United States Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region in 2026
Figure 48. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Region (2021-2026)
Figure 49. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2021-2026)
Figure 50. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2021-2026)
Figure 51. China Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 55. India Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country in 2026
Figure 59. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2021-2026)
Figure 60. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2021-2026)
Figure 61. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2021-2026)
Figure 62. Germany Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 63. France Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2021-2026)
Figure 70. Egypt Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer in 2026
Figure 76. Manufacturing Process Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer
Figure 77. Industry Chain Structure of Monoclonal Antibodies for Non-small Cell Lung Cancer
Figure 78. Channels of Distribution
Figure 79. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Forecast by Region (2027-2032)
Figure 80. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Monoclonal Antibodies for Non-small Cell Lung Cancer
Figure 2. Monoclonal Antibodies for Non-small Cell Lung Cancer Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country/Region (2025)
Figure 10. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 5 mg/mL
Figure 12. Product Picture of 10 mg/mL
Figure 13. Product Picture of 25 mg/mL
Figure 14. Product Picture of 50 mg/mL
Figure 15. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type in 2026
Figure 16. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Type (2021-2026)
Figure 17. Monoclonal Antibodies for Non-small Cell Lung Cancer Consumed in Hospitals
Figure 18. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Hospitals (2021-2026) & (K Units)
Figure 19. Monoclonal Antibodies for Non-small Cell Lung Cancer Consumed in Clinic
Figure 20. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Clinic (2021-2026) & (K Units)
Figure 21. Monoclonal Antibodies for Non-small Cell Lung Cancer Consumed in Others
Figure 22. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market: Others (2021-2026) & (K Units)
Figure 23. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sale Market Share by Application (2025)
Figure 24. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Application in 2026
Figure 25. Monoclonal Antibodies for Non-small Cell Lung Cancer Sales by Company in 2026 (K Units)
Figure 26. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Company in 2026
Figure 27. Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue by Company in 2026 ($ millions)
Figure 28. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Company in 2026
Figure 29. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales 2021-2026 (K Units)
Figure 32. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue 2021-2026 ($ millions)
Figure 33. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales 2021-2026 (K Units)
Figure 34. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue 2021-2026 ($ millions)
Figure 35. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales 2021-2026 (K Units)
Figure 36. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue 2021-2026 ($ millions)
Figure 39. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country in 2026
Figure 40. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2021-2026)
Figure 41. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2021-2026)
Figure 42. Americas Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2021-2026)
Figure 43. United States Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Region in 2026
Figure 48. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Region (2021-2026)
Figure 49. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2021-2026)
Figure 50. APAC Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2021-2026)
Figure 51. China Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 55. India Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country in 2026
Figure 59. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share by Country (2021-2026)
Figure 60. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2021-2026)
Figure 61. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2021-2026)
Figure 62. Germany Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 63. France Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share by Application (2021-2026)
Figure 70. Egypt Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer in 2026
Figure 76. Manufacturing Process Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer
Figure 77. Industry Chain Structure of Monoclonal Antibodies for Non-small Cell Lung Cancer
Figure 78. Channels of Distribution
Figure 79. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Forecast by Region (2027-2032)
Figure 80. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Revenue Market Share Forecast by Application (2027-2032)
